Combining cutting edge computational and experimental methods for targeting KRAS mutations in non-small cell lung cancer.

Abstract excerpt

INTRODUCTION: Historically, KRAS mutations have been notoriously difficult to target despite their status as the most commonly mutated oncogene in the RAS gene family. Pioneering work by Shokat and colleagues has led to the discovery of KRAS G12C-GDP mutant-specific inhibitors, with two such inhibitors adagrasib and sotorasib now FDA approved for treatment of non-small cell lung cancer (NSCLC). Unfortunately,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antineoplastic Agents
• Share to Artificial Intelligence